Experimental psychosis research with hallucinogenic drugs - Past and present;Experimentelle psychoseforschung mit halluzinogenen substanzen - Geschicte und gegenwart

Nervenheilkunde

Volumn 18, Issue 2, 1999, Pages 84-92

  Gouzoulis Mayfrank, Euphrosyne ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Experimental psychosis; Hallucinogens; Model psychosis

Indexed keywords

KETAMINE; LYSERGIDE; MESCALINE; N,N DIMETHYLTRYPTAMINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSILOCYBINE; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT;

ARTICLE; MEDICAL RESEARCH; NEGATIVE SYNDROME; NEUROBIOLOGY; NEUROTRANSMITTER RELEASE; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 0032892611     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: Promise and pitfalls. Pharmacopsychiat 1998; 31 S: 104-9.
2. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction 1993; 88: 1327-34.
3. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of Ketamine on thought disorder, working memory and semanctic memory in healthy volunteers. Biol Psychiatry 1998; 43: 811-6.
4. Anastasopoulos G, Photiades H. Effects of LSD-25 on relatives of schizophrenic patients. J Ment Sci 1962; 108: 95-8.
5. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79: 565-75.
6. Beringer K. Experimentelle Psychosen durch Meskalin. Z Neurol Psychiat 1923; 84: 426-33.
7. Beringer K. Der Meskalinrausch. Heidelberg, Berlin: Springer 1927.
8. Beringer K. Die Bedeutung der Rauschgiftversuche für die Klinik. Schweiz Arch Neurol Psychiat 1932; 28: 1-17.
9. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990; 47: 181-8.
10. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992; 49: 206-15.
11. Bunney BG, Bunney Jr. WE, Carlsson A. Schizophrenia and Glutamate. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, Ltd. New York 1995; pp 1205-14.
12. Catafau AM, Parellada E, Lomena FJ, et al. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med 1994; 35: 935-41.
13. Cleghorn JM, Garnett ES, Nahmias C et al. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res 1989; 28: 119-33.
14. Cohen S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 1960; 130: 30-40.
15. Cole JO, Katz MM. The Psychotomimetic Drugs. An Overview. JAMA 1964; 187: 758-61.
16. Devous MD Sr, Trivedi MH, Gong W, Harris TS, Rush AJ. rCBF changes in limbic and limbically innervated brain regions in normal controls following oral amphetamine challenge. J Cerebral Blood Flow Metabolism 1995; 15: S 829.
17. Duncan E, Parwani A, Madonick S, et al. Ketamine effects on prepulse inhibition of startle in normals. American College of Neuropsychopharmacology Abstracts, 1997; p 299.
18. Ebmeier KP, Blackwood DHR, Murray C, et al. Single-photon emission computed tomography with 99mTc-Exametazime in unmedicated schizophrenic patients. Biol Psychiatry 1993; 33: 487-95.
19. Ellis H (1897) Mescal: A new artificial paradise. Annual Report of the Smithsonian Institution 1897; 537-48.
20. Emrich HM. A three-component-system hypothesis of psychosis. Impaired binocular depth inversion as an indicator of functional Disequilibrium. Br J Psychiatry 1989; 155, S 5: 37-9.
21. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997; 56: 803-7.
22. Erard R, Luisada PV, Peele R. The PCP Psychosis: Prolonged Intoxication or Drug-Precipitated Funcional Illness? J Psychedelic Drugs 1980; 12: 235-51.
23. Fischer R, Georgi F, Weber R. Psychophysische Korrelationen. VIII. Modellversuche zum Schizophrenieproblem. Lysergsäurediäthylamid und Mescalin. Schweiz Med Wschr 1951; 81: 817-8.
24. Fischer R, Griffin F, Liss L. Biological aspects of time in relation to (model) psychosis. Ann New York Acad Sci 1962; 96: 44-65.
25. Fischer R, Marks PA, Rockey MA. Der Einfluß der Struktur der Persönlichkeit auf den Ausgang der Modellpsychose. Arzneimittelforschung 1969; 19: 478-80.
26. Gaddum JH. Antagonism between lysergic acid diethylamide and 5-hydroxy-tryptamine. J Physiol 1953; 121: 15 P.
27. Gaddum JH, Vogt M. Some central actions of 5-hydroxytryptamine and various antagonists. Brit J Pharmacol 1956; 11: 175-9.
28. Gaddum JH, Hammed KA, Hathway DE, Stephens FF. Qantitative studies of antagonists for 5-hydroxytryptamine. Quart J Exper Physiol 1955; 40: 49-71.
29. Geyer MA. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiat 1998; 31 S: 73-9.
30. Geyer MA, Markou A. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology, The fourth generation of progress, Raven Press, Ltd, New York 1995; pp 787-98.
31. Gillin JC, Kaplan J, Stillman R, Wyatt RJ. The psychedelic model of schizophrenia: The case of N,N-Dimethyltryptamine. Am J Psychiatry 1976; 133: 203-8.
32. Gouzoulis E, Hermle L, Sass H. Psychedelische Erlebnisse zu Beginn produktiver Episoden endogener Psychosen. Nervenarzt 1994; 65: 198-201.
33. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Kovar KA, Sass H, Geyer M. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in healthy humans. Behav Pharmacology 1998; 9: 561-6.
34. Gouzoulis-Mayfrank E, Thelen B, Hermle L, Sass H. History, rationale and potential of human experimental research with hallucinogenic drugs in psychiatry. Pharmacopsychiat 1998; 31 S2: 63-8.
35. Gouzoulis-Mayfrank E, Thelen B, Maier S, Habermeyer E, Spitzer M, Sass H. Modulation of semantic priming effects by psilocybin, MDE (ecstasy), and d-methamphetamine - Principles and applications of the model psychosis strategy. Neurol, Psychiat & Brain Res 1998; 6: 19-28.
36. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning CH, Thelen B, Hermle L, Spitzer M, Bull U, Sass H. Neurometabolic effects of psilocybin, 3,4-Methylenedioxyethamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999 (in Druck).
37. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Hermle L, Kovar KA, Spitzer M, Sass H. Psychopathological, neuroendocrine and autonomie effects of 3,4-Methylenedioxyethamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology 1999 (in Druck).
38. Grinker RR. Lysergic Acid Diethylamide. Arch Gen Psychiatry 1963; 8: 425.
39. Grinker RR. Bootlegged Ecstasy. JAMA 1964; 187: 192.
40. Heffter A. Über Cacteenalkaloide. Ber Dtsch Chem Ges 1898; 31: 1193.
41. Heimann H. Ausdrucksphänomenologie der Modellpsychosen (Psilocybin). Psychiat Neurol 1961; 141: 69-100.
42. Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M. Mescaline-induced psychopathological, neuropsychological and neurometabolic effects in normal subjects. Experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992; 32: 976-91.
43. Hermle L, Gouzoulis E, Oepen G, Spitzer M, Kovar K-A, Borchardt D, Fünfgeld M, Berger M. Die Bedeutung der historischen und aktuellen Halluzinogenforschung in der Psychiatrie. Nervenarzt 1993; 64: 562-71.
44. Hoch PH. The problem of schizophrenia in the light of experimental psychiatry. Proceedings Amer Psychopath Assoc 1957; 205-17.
45. Hoch PH, Cattell JP, Pennes HH. Effects of mescaline and lysergic acid (d-LSD-25). Am J Psychiatry 1952; 108: 579-84.
46. Hoch PH, Pennes HH, Catell JP. Psychoses produced by administration of drugs. Assoc Res Nerv Ment Dis Proc 1953; 32: 287-96.
47. Hoffer A, Osmond H. The adenochrome model and schizophrenia. J Nerv Ment Dis 1959; 128: 18-35.
48. Hoffer A, Osmond H, Smythies J. Schizophrenia: a new approach. II. Result of a year's research. J Ment Sci 1954; 100: 29-45.
49. Jaensch W. Pharmakologische Versuche über die Beziehungen optischer Konstitutionsstigmen zu den Halluzinationen. Zbl Ges Neurol Psychiat 1920; 23: 119-20.
50. Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) Model of Schizophrenia. Hillside J Clin Psychiat 1987; 9: 12-35.
51. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
52. Kahn DA, Prohovnik I, Lucas LR, et al. Disassociated effects of amphetamine on arousal and cortical blood flow in humans. Biol Psychiatry 1989; 25: 755-67.
53. Karper LP, Grillon C, Abi-Saab D, Morgan III CA, Charney DS, Krystal JH. The effect of ketamine on pre-pulse inhibition and attention. Schizophrenia Res 1995; 15: 180.
54. Klüver H. Mescal visions and eidetic vision. Am J Psychology 1928; 37: 502-13.
55. Knauer A, Maloney WJMA. A preliminary note on the psychic action of mescaline with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 1913; 40: 425-36.
56. Krystal JH, Karper LP, Seibyl JP, et al. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
57. Krystal JH, Karper LP, Bennett A, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998; 135: 213-29.
58. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 1995; 6: 869-72.
59. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanaesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
60. LaPorte DJ, Lahti AC, Koffel B, Tamminga CA. Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. J Psychiat Res 1996; 30: 321-30.
61. Leuner HC. Die experimentelle Psychose. Ihre Psychopharmakologie, Phänomenologie und Dynamik in Beziehung zur Person. Berlin: Springer 1962.
62. Leuner HC. Halluzinogene: Psychische Grenzzustände in Forschung und Psychotherapie. Bern: Huber 1981.
63. Lewin L. Über Anhalonium Lewinii. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 1888; 24: 401.
64. London ED, Broussole EPM, Links JM, et al. Morphine-induced metabolic changes in human brain: studies with positron emission tomography and [fluorine 18] fluorodeoxyglucose. Arch Gen Psychiatry 1990a; 47: 73-81.
65. London ED, Cascella NG, Wong DF, et al. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [Fluorine 18]-Fluorodeoxyglucose. Arch Gen Psychiatry 1990b; 47: 567-74.
66. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a New Schizophrenomimetic Drug - Sernyl. A.M.A. Arch Neurol Psychiat 1959; 71: 363-9.
67. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 301-7.
68. Malleson N. Acute Adverse Reactions to LSD in Clinical and Experimental Use in the United Kingdom. Br J Psychiat 1971; 118: 229-30.
69. Manschreck TC, Maher BA, Milavetz JJ, Ames D, Weisstein CC, Schneyder ML. Semantic priming in thought-disordered schizophrenic patients. Schizophrenia Res 1988; 1: 61-6.
70. Mathew RJ, Wilson WH. Substance abuse and cerebral blood flow. Am J Psychiatry 1991; 148: 292-305.
71. Mayer-Gross W, Stein H. Über einige Abänderungen der Sinnestätigkeit im Meskalinrausch. Zeitschr Ges Neurol Psychiat 1926; 101: 354-86.
72. Metz JT, de Wit H, Cooper M. Amphetamine and regional cerebral metabolic rate: Effects of behavioral state and dose. J Cerebral Blood Flow Metab 1991; 11 (suppl 2): S 390.
73. Mitchell SW. The effects of Anhalonium Lewinii (the mescal button). BMJ 1896; 2: 1625-9.
74. Osmond H, Smythies J. Schizophrenia: a new approach. J Ment Sci 1952; 98: 309-15.
75. Parellada E, Catafau AM, Bernardo M, et al. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatry Res Neuroimag 1994; 55: 131-9.
76. Pearlson GD. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. John Hopkins Med J 1981; 148: 25-33.
77. Pechnick RN, Ungerleider JT. Hallucinogens. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds). Substance Abuse. A comprehensive textbook, 3rd ed. Baltimore, Maryland: Williams and Wilkins 1997, pp 230-8.
78. Prentiss DW, Morgan A. Anhalonium Lewinii (mescal buttons): a study of the drug with especial references to the physiological action upon man with report of experiments. Ther Gaz 1895; 9 (zitiert nach: Beringer 1927).
79. Rinkel M, Deshon HJ, Hyde RW, Solomon HC. Experimental schizophrenia-like symptoms. Am J Psychiatry 1952; 108: 572-8.
80. Rinkel M, Hyde RW, Solomon HC, Hoagland H. Experimental Psychiatry II, Clinical and Physio-Chemical Observations in Experimental Psychosis. Am J Psychiatry 1955; 111: 881-95.
81. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D. Comparison of Sernyl with other drugs. Arch Gen Psychiatry 1959; 1: 113-8.
82. Roth BL, Meltzer HY. The Role of Serotonin in Schizophrenia. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press 1995; pp 1215-27.
83. Savage C, Cholden L. Schizophrenia and the Model Psychoses. J Clin Exper Psychopathol 1956; 17: 405-13.
84. Schneider U, Leweke FM, Sternemann U, Weber MM, Emrich HM. Visual illusion: a systems-theoretical approach to psychosis. Eur Arch Psychiatry Clin Neurosci 1996; 246: 256-60.
85. Schneider U, Leweke FM, Mueller-Vahl KR, Emrich HM . Cannabinoid/amandamide-system and schizophrenia: is there evidence for an association? Pharmacopsychiat 1998; 31 S: 110-3.
86. Sedmann G, Kenna JC. The use of LSD-25 as a diagnostic aid in doubtful cases of schizophrenia. Br J Psychiatry 1965; 111: 509.
87. Spaeth E. Über Anhalonium-Alkaloide. I. Anhalin und Meskalin. Monatssch Chemie 1918; 40: 129.
88. Spitzer M, Braun U, Hermle L, Maier S. Associative semantic network dysfunction in thought-disordered schizophrenic patients: Direct evidence from indirect semantic priming. Biol Psychiatry 1993; 34: 864-77.
89. Spitzer M, Braun U, Maier S, Hermle L, Maher BA. Indirect semantic priming in schizophrenic patients. Schizophrenia Res 1993; 11: 71-80.
90. Spitzer M, Thimm M, Hermle L, Holzman P, Schneider F, Gouzoulis-Mayfrank E, Kischka U, Kovar K-A. Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry 1996; 39: 1055-7.
91. Strassman RJ. Averse Reactions to Psychedelic Drugs. A Review of the Literature. J Nerv Ment Dis 1984; 172: 577-95.
92. Van Praag HM. Two-tier diagnosing in psychiatry. Psychiatry Res 1990; 34: 1-11.
93. Vollenweider FX. Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research. Pharmacopsychiat 1998; 31: 92-103.
94. Vollenweider FX, Antonini A, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by S-and R-ketamine in healthy volunteers measured by FDG-PET. Eur Neuropsychopharmacology 1997; 7: 25-38.
95. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) Eur Neuropsychopharmacology 1997; 7: 9-24.
96. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997; 16: 357-72.
97. Vollenweider FX, Liechti M, Gamma A, Hell D, Geyer M. Effects of MDMA (Ecstasy) on sensorimotor gating, attention, and mood in healthy volunteers. Abstracts: International Congress on The State of the Art in Psychiatry, June 19-21, 1997, Basel, Switzerland 1997d, p 28.
98. Wolkin A, Angrist B, Wolf A, et al. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology 1987; 92: 241-6.
99. Zádor J. Meskalinwirkung bei Störungen des optischen Systems. Z Neurol Psychiat 1930; 127: 30-107.
100. Zucker K. Versuche mit Meskalin an Halluzinanten. Z Neurol Psychiat 1930; 127: 108-61.